Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- Researchers recognize that a large share of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity.
- That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions.
- Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery.
Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies building a therapy around that shift, through its myelin-focused candidate Lucid-MS.
For decades, MS treatment success was measured largely by relapse rates. Fewer flare-ups meant a drug was working. But researchers now recognize that a substantial proportion of long-term disability accumulates independent of…
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN